体质 PRS 分层试验的应答衰减斜率:遗传负荷压制干预,是全表型通用还是通路特异?

Written by

in

Language

Evidence level: B

体质 PRS 分层 RCT 隐含一个假设——高遗传负荷者的干预应答会被压制;但把四个终点的衰减斜率摆在一起,这个”通用压制”假设可能只在个别通路上成立。

正文

中医九种体质的多基因风险评分(PRS)分层随机对照试验(RCT),是”辨体论治”走向量化证据的关键设计:先按体质 PRS 把人群分成高/低遗传负荷两层,再看生活方式干预在两层里的应答差异。这个设计默认了一个前提——遗传负荷高的人,干预效果会衰减,即”先天禀赋压制后天调理”。但衰减是真实现象还是设计假设?如果衰减存在,它是代谢通路特异还是全表型通用?把四个终点(血糖、体重、脂质、体质量表评分)的衰减斜率摆在一起对比,答案并不统一——现有的随机试验证据呈现出三种截然不同的模式。

血糖终点:衰减存在,但干预依然有效。 糖尿病预防计划(DPP)是迄今证据最硬的战场。2016 年的一项分析(PMID 26525880)用 17 个已确认的胰岛素抵抗变异构建加权遗传风险评分(IR-GRS),在 2713 名 DPP 参与者中检验:高 IR-GRS 者基线胰岛素敏感性指数(ISI)更低(β=−0.754,P=0.001),一年后 ISI 改善也确实被衰减(β=−0.520,P=0.03,所有治疗组一致)——衰减斜率存在,且跨安慰剂、二甲双胍、生活方式三组一致。但关键在交互项:治疗×IR-GRS 的交互 P=0.54,完全不显著。也就是说,高遗传负荷者的改善被”压低了一截”,但生活方式干预和二甲双胍在三组里照样改善 ISI,”压制”没有改变治疗的相对获益。后续用 34 个 2 型糖尿病位点构建的更新版 GRS 复现了同一格局:GRS 每增加一个风险等位基因,进展为糖尿病的 HR=1.02、回归正常血糖的 HR=0.95,但 GRS×治疗无显著交互,且生活方式干预在 GRS 最高四分位里依然显著有效(P<0.0001)。血糖通路的衰减模式是”平移下压、斜率不变”——干预仍然有效,只是起点更低。

体重终点:衰减不在减重期,而在维持期。 2026 年发表的妇女健康倡议(WHI)饮食干预试验分析(PMID 41792585)给出了一个更精细的答案。9897 名绝经后妇女(6132 名欧裔、3749 名非裔)随访 7 年:第一年强化干预期(18 次/年),两组减重无差异;进入低强度维持期(4 次/年)后,PRS 第 95 百分位以上的欧裔妇女以每年 0.94 kg 的速度反弹,几乎是普通风险组(0.48 kg/年)的两倍(P=0.0016)。注意这个模式与血糖完全不同:衰减斜率不在”压下去”的阶段,而在”守得住”的阶段——遗传负荷不阻止你减重,但加速你反弹。更麻烦的是非裔美国人组方向完全相反:高 PRS 者在干预组维持住减重成果(−0.10 kg/年,P=0.48),反而是低 PRS 者每年增重 0.25 kg(P<0.001)。同一个 PRS,在同一个试验里,两个祖源亚组的衰减斜率方向相反——这直接警告:衰减斜率本身受人群背景调制。

脂质终点:衰减不是单调的,方向随饮食类型翻转。 RISCK 随机饮食干预试验的 APOE 基因型分析(PMID 30336580)展示了第三种模式。469 名代谢综合征风险人群随机到五种等能量饮食(饱和脂肪替换为单不饱和脂肪或高/低升糖指数碳水),24 周后发现:APOE E4 携带者在”低脂+低升糖碳水”替换饱和脂肪时,总胆固醇和 apoB 降幅显著更大(TC p=0.02、apoB p=0.006);但同样是 E4 携带者,在”单不饱和脂肪+高升糖碳水”替换时总胆固醇反而相对升高(TC +0.3 mmol/L,P=0.03);E2 携带者则在特定替换下甘油三酯升高 0.46 mmol/L(P=0.001)。脂质通路的”遗传压制”不是一条向下的斜线,而是一个随干预内容翻转的交互——同一个基因型可以”增益”也可以”受损”,取决于你换了哪种脂肪酸。这意味着脂质终点的衰减斜率如果只按高/低 PRS 分两层建模,会把方向相反的效应平均成”无交互”的假象。

体脂终点:GRS 敏感度分层本身有梯度。 韩国 KoGES 队列(n=8840,PMID 29495392)提供了第四个参照:在 673 个肥胖相关 SNP 中筛出 100 个具有基因×环境交互效应的位点构建 GRS,把人群分成”非常不敏感/不敏感/敏感/非常敏感”四层,体脂下降量随敏感度层级单调递增——遗传负荷不是”压制”干预,而是决定你对饮食和运动的”响应灵敏度”。这个框架与血糖、体重、脂质三种模式都兼容:灵敏度梯度可以被理解为衰减斜率的镜像。

裁决:衰减斜率是通路特异的,”通用压制”假设不成立。 四终点并置的结论很清楚:血糖=平移下压但干预仍有效;体重=衰减滞后出现在维持期且祖源方向相反;脂质=交互方向随饮食类型翻转;体脂=敏感度梯度而非简单压制。没有哪个终点支持”高 PRS 在所有表型上以同一斜率压制干预”的朴素假设。对九种体质 PRS 分层 RCT 的直接影响有三条:其一,体质评分作为复合终点必须逐维度(血糖/体重/脂质)分别建模衰减斜率,任何”总体衰减系数”都会掩盖通路特异结构;其二,体质 PRS 分层试验应预设”减重期 vs 维持期”双阶段分析,因为体重通路的衰减主战场在维持期;其三,脂质通路必须按干预内容(脂肪酸构成)报告基因型×干预交互,而不是只报告主效应。中医体质”同病异治”的现代版本,可能恰恰就是这张通路特异的衰减斜率表。

证据与局限

已验证: DPP 中高 IR-GRS 与 ISI 改善衰减相关(β=−0.520,P=0.03)但治疗交互不显著(PMID 26525880);WHI 中高 PRSBMI 欧裔妇女维持期体重反弹斜率近两倍(0.94 vs 0.48 kg/年,P=0.0016)且非裔方向相反(PMID 41792585);RISCK 中 APOE 基因型×饮食交互显著且方向随替换类型翻转(PMID 30336580);KoGES 中 GRS 敏感度四层与体脂下降梯度单调对应(PMID 29495392)。

部分验证: DPP 34 位点 GRS 复现”衰减存在、交互不显著、高 GRS 四分位干预仍有效”格局,但效应量小(HR=1.02/等位基因);衰减斜率的祖源异质性(欧裔 vs 非裔)仅单一试验支持。

待验证: ①九种体质 PRS 分层 RCT 的四终点衰减斜率是否复现上述三模式(血糖平移/体重滞后/脂质翻转);②体质量表评分的衰减斜率属于哪种模式——若与血糖同构(平移下压但干预仍有效),则”辨体干预”对高 PRS 者仍应推荐而非放弃;③脂质翻转模式在东亚人群(低饱和脂肪摄入基线)中是否同样出现。

相关阅读

证据等级: B
参考文献: PMID 26525880, PMID 41792585, PMID 30336580, PMID 29495392


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Response Decay Slopes in Phenotype-Based Polygenic Risk Score Stratification Trials: Do Genetic Burdens Suppress Interventions Universally Across All Phenotypes or Specifically…

Evidence level: B

The stratified RCT design for physiological PRS implies a hypothesis—that intervention response in high genetic load individuals is suppressed; however, juxtaposing decay slopes across four endpoints suggests this “universal suppression” hypothesis may hold true only for specific pathways.

Main Text

The multi-physiotype PRS stratified randomized controlled trial (RCT) represents a critical design step in quantifying “differentiation of constitution for treatment”: first stratifying the population into high/low genetic load layers based on physiological PRS, then comparing intervention responses between these layers. This design presupposes that individuals with high genetic load experience attenuated intervention efficacy, a concept termed “inherent constitution suppresses postnatal regulation.” However, is attenuation an empirical phenomenon or a design artifact? If attenuation exists, is it pathway-specific or universally general across phenotypes? By juxtaposing decay slopes across four endpoints (glucose, weight, lipids, and body mass index), the evidence reveals a non-uniform pattern—existing randomized trials present three distinct modes.

Glucose Endpoint: Attenuation Exists, Yet Intervention Remains Effective. The Diabetes Prevention Program (DPP) remains the most robust evidence base. A 2016 analysis (PMID 26525880) constructed a weighted genetic risk score (IR-GRS) using 17 confirmed insulin resistance variants and tested it across 2,713 DPP participants. Findings indicated that high IR-GRS individuals exhibited lower baseline insulin sensitivity index (ISI) ($\beta=-0.754$, $P=0.001$), and ISI improvement over one year was indeed attenuated ($\beta=-0.520$, $P=0.03$) consistently across all treatment groups—confirming the existence of a decay slope. Crucially, however, the interaction term (Treatment $\times$ IR-GRS) yielded $P=0.54$, indicating no statistical significance. Thus, while improvement in high genetic load individuals was “flattened,” lifestyle intervention and metformin still improved ISI across all three groups; the “suppression” did not alter the relative benefit of treatment. A subsequent update using 34 type 2 diabetes loci replicated this pattern: for each additional risk allele, the hazard ratio (HR) for progression to diabetes was 1.02 and for regression to normal glucose was 0.95, yet no significant interaction existed between GRS and treatment, with lifestyle intervention remaining significantly effective in the highest GRS quartile ($P<0.0001$). The glucose pathway exhibits a “parallel shift downward with invariant slope” pattern—the intervention remains effective, merely starting from a lower baseline.

Weight Endpoint: Attenuation Occurs Not During Weight Loss, But During Maintenance. The 2026 analysis of the Women’s Health Initiative (WHI) dietary intervention trial (PMID 41792585) provided a more nuanced answer. Following 9,897 postmenopausal women (6,132 European ancestry, 3,749 African ancestry) for 7 years: during the first year of intensive intervention (18 sessions/year), weight loss showed no difference between groups; however, entering the low-intensity maintenance phase (4 sessions/year), European ancestry women in the top 95th percentile of PRS rebounded at 0.94 kg/year, nearly double the rate of the average risk group (0.48 kg/year; $P=0.0016$). Note that this pattern differs fundamentally from glucose: the decay slope does not manifest during the “weight loss” phase but during the “maintenance” phase—genetic load does not prevent weight loss but accelerates rebound. Complicating matters further, the direction was entirely reversed in the African American subgroup: high PRS individuals maintained weight loss results ($-0.10$ kg/year, $P=0.48$), whereas low PRS individuals gained weight at 0.25 kg/year ($P<0.001$). The same PRS within the same trial yielded opposite decay slopes across two ancestral subgroups—directly warning that decay slopes themselves are modulated by population background.

Lipid Endpoint: Attenuation Is Not Monotonic; Direction Flips Based on Diet Type. The APOE genotype analysis from the RISCK randomized dietary intervention trial (PMID 30336580) demonstrated a third mode. Among 469 individuals at metabolic syndrome risk randomly assigned to five iso-caloric diets (replacing saturated fat with monounsaturated fat or high/low glycemic index carbohydrates), 24 weeks revealed that APOE E4 carriers showed significantly greater reductions in total cholesterol and apoB when replacing saturated fat with “low-fat + low glycemic index carbs” (TC $p=0.02$, apoB $p=0.006$); conversely, the same E4 carriers showed relatively increased total cholesterol when replacing with “monounsaturated fat + high glycemic index carbs” (TC $+0.3$ mmol/L, $P=0.03$); and E2 carriers showed elevated triglycerides by 0.46 mmol/L under specific substitutions ($P=0.001$). The “genetic suppression” in the lipid pathway is not a single downward slope but an interaction that flips direction based on intervention content—the same genotype can yield “gain” or “loss” depending on the specific fatty acid substituted. This implies that modeling lipid endpoint decay slopes using only high/low PRS stratification would average opposing effects into a false appearance of “no interaction.”

Body Fat Endpoint: GRS Sensitivity Stratification Itself Exhibits Gradients. The Korean KoGES cohort ($n=8,840$, PMID 29495392) provided a fourth reference: screening 673 obesity-associated SNPs identified 100 loci exhibiting gene-by-environment interactions to construct a GRS, stratifying the population into four layers (“very insensitive,” “insensitive,” “sensitive,” “very sensitive”). Body fat reduction increased monotonically with sensitivity layers—genetic load does not merely “suppress” intervention but determines the “response sensitivity” to diet and exercise. This framework is compatible with the glucose, weight, and lipid modes: the sensitivity gradient can be conceptualized as a mirror image of the decay slope.

Verdict: Decay Slopes Are Pathway-Specific; “Universal Suppression” Hypothesis Fails. The conclusion from juxtaposing four endpoints is clear: glucose = parallel shift downward but intervention remains effective; weight = attenuation delayed to maintenance phase with opposite directions across ancestry; lipid = interaction direction flips based on diet type; body fat = sensitivity gradient rather than simple suppression. No endpoint supports the naive hypothesis that “high PRS suppresses intervention at the same slope across all phenotypes.” The direct implications for nine-physiotype PRS stratified RCTs are threefold: first, physiological scores as composite endpoints must model decay slopes dimension-by-dimension (glucose/weight/lipids); any “overall decay coefficient” would obscure pathway-specific structures; second, PRS stratified trials should pre-specify “weight loss vs. maintenance” dual-phase analyses, as the weight pathway’s primary battlefield for attenuation is the maintenance phase; third, the lipid pathway must report genotype-by-intervention interactions based on intervention content (fatty acid composition) rather than solely reporting main effects. The modern version of TCM’s “same disease, different treatment” may precisely correspond to this table of pathway-specific decay slopes.

Evidence and Limitations

Verified: DPP showed attenuation between high IR-GRS and ISI improvement ($\beta=-0.520$, $P=0.03$) but no significant treatment interaction (PMID 26525880); WHI showed near-doubled weight rebound slope in European ancestry high PRS BMI women during maintenance (0.94 vs 0.48 kg/year, $P=0.0016$) with opposite direction in African ancestry (PMID 41792585); RISCK showed significant APOE genotype-by-diet interaction with direction flipping based on substitution type (PMID 30336580); KoGES showed monotonic correspondence between four GRS sensitivity layers and body fat reduction gradient (PMID 29495392).

Partially Verified: DPP 34-locus GRS replicated the pattern of “attenuation exists, no significant interaction, intervention still effective in highest quartile,” though effect sizes were small (HR=1.02 per allele); ancestry heterogeneity of decay slopes (European vs. African) supported by only a single trial.

To Be Verified: ① Whether the four endpoint decay slopes in nine-physiotype PRS stratified RCTs replicate the three modes above (glucose shift/weight lag/lipid flip); ② Which mode applies to body mass index decay slopes—if isomorphic to glucose (shift downward but intervention effective), “constitution-based intervention” should still be recommended for high PRS individuals rather than abandoned; ③ Whether the lipid flip pattern occurs in East Asian populations (lower baseline saturated fat intake).

Related Reading

Evidence Level: B
References: PMID 26525880, PMID 41792585, PMID 30336580, PMID 29495392


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *